4D Molecular Therapeutics Inc (FDMT) returns
4D Molecular Therapeutics returns over 5 years
$1,000 invested in 4D Molecular Therapeutics five years ago was worth $495.21 at the close on October 30, 2026, with dividends reinvested: an average return of -13.1% a year. The same $1,000 in the S&P 500 (SPY) became $1,760.
Total return by period
| Period | Total return | A year, on average | $1,000 became | S&P 500 (SPY) |
|---|---|---|---|---|
| 1 month | -16.8% | — | $831.59 | -0.9% |
| 3 months | +18.2% | — | $1,182 | +2.1% |
| Year to date | +58.7% | — | $1,587 | +11.7% |
| 1 year | +5.1% | — | $1,051 | +12.4% |
| 3 years | +11.9% | +3.8% | $1,119 | +88.5% |
| 5 years | -50.5% | -13.1% | $495.21 | +76.0% |
4D Molecular Therapeutics return by calendar year
| Year | FDMT | S&P 500 (SPY) | Difference |
|---|---|---|---|
| 2026 to date | +58.7% | +11.7% | +47.0% |
| 2025 | +34.6% | +17.7% | +16.9% |
| 2024 | -72.5% | +24.9% | -97.4% |
| 2023 | -8.8% | +26.2% | -35.0% |
| 2022 | +1.2% | -18.2% | +19.4% |
| 2021 | -47.1% | +28.7% | -75.8% |
Past returns do not predict future returns. Returns are computed from our daily closes, adjusted for splits and with dividends reinvested on their ex-dates; taxes and trading costs are left out.
See also: FDMT financials
No forecast, no recommendation. This page describes 4D Molecular Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.